Influenza in at risk groups only
Refer to Local Antimicrobial Formulary see link on section 5
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza February 2009
| Pack | Price |
|---|---|
| 10 capsule | £15.41 |
Influenza in at risk groups only
Refer to Local Antimicrobial Formulary see link on section 5
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza February 2009
| Pack | Price |
|---|---|
| 20 blister | £16.36 |
COVID-19
First oral antiviral for COVID-19, Lagevrio (molnupiravir)
Hospitalised adults and children aged 18 years and older with COVID-19 who are symptomatic and showing no evidence of clinical recovery
Rationale 1
Treating COVID-19
Rationale 1,3
Covid Pneumonia
Rationale 1,2,3
NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical
Treating Covid-19
Rationale 1,3
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 NICE TA971
Covid-19 Pneumonia - Infusion only
Rationale 1,3
Adults who are having systemic corticosteroids and require supplemental oxygen or mechanical ventilation
| Pack | Price |
|---|---|
| 1 vial | £256.00 |
| Pack | Price |
|---|---|
| 1 vial | £512.00 |
| Pack | Price |
|---|---|
| 1 vial | £102.40 |
| Pack | Price |
|---|---|
| 1 vial |
| Pack | Price |
|---|---|
| 1 vial |
| Pack | Price |
|---|---|
| 1 vial |
| Pack | Price |
|---|---|
| 1 vial | £230.40 |
| Pack | Price |
|---|---|
| 1 vial | £460.80 |
| Pack | Price |
|---|---|
| 1 vial | £92.16 |
Influenza A prophylaxis & treatment
Rationale 1
Amantadine is not recommended for the treatment of influenza.
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza February 2009 guidance reviewed Nov 2014
Amantadine is not recommended for the prophylaxis of influenza
NICE TA158 Influenza (prophylaxis) - Amantadine, Oseltamivir and Zanamivir: Guidance Sept 2008
Uncomplicated influenza and post exposure prophylaxis of influenza in patients aged 12 years and above.
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating and preventing influenza in children 1 to 11 years. This is because the company did not provide an evidence submission.
Treatment of Covid-19 (off-label) in adults over 50 years old.
Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19
NICE NG191 COVID-19 rapid guideline: managing COVID-19